ロード中...

Tolvaptan, hyponatremia, and heart failure

Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...

詳細記述

保存先:
書誌詳細
主要な著者: Zmily, Hammam D, Daifallah, Suleiman, Ghali, Jalal K
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2011
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/
https://ncbi.nlm.nih.gov/pubmed/21694950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!